Soligenix

Soligenix awarded $24.7M NIAID contract for heat stable RiVax vaccine

Friday, September 26, 2014

Soligenix, a Princeton, N.J.-based late-stage biopharmaceutical company developing products that address unmet medical needs in inflammation, oncology and biodefense, has been awarded a contract valued at up to $24.7 million inclusive of options by the U.S. Department of Health and Human Service‘s NIH, specifically funded by the National Institute of Allergy and Infectious Diseases (NIAID). The objectives of the contract are to advance the development of Soligenix’s thermostabilization technology, ThermoVax, combined with the company’s ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.

[Read More]

Soligenix recieves $300,000 NIAID SBIR grant award for Melioidosis

Friday, February 14, 2014

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.

[Read More]

Soligenix appoints Richard Straube chief medical officer

Tuesday, January 7, 2014

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, has appointed Richard Straube, M.D., as its senior vice president and chief medical officer.

[Read More]

Soligenix awarded NIAID contract

Wednesday, October 2, 2013

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) for which there remains an unmet medical need, has been awarded a contract valued at up to $6.4 million by the U.S. Department of Health and Human Service’s NIH (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

[Read More]

Soligenix, SciClone collaborate in personalized medicine

Monday, July 8, 2013

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there is an unmet medical need, has announced a personalized medicine collaboration with SciClone Pharmaceuticals in the company’s oral mucositis clinical program with SGX942. Soligenix will receive access to SciClone’s oral mucositis clinical and regulatory data library in exchange for commercialization rights in China, including Hong Kong and Macau.

[Read More]

Soligenix completes phase I in SGX203 for pediatric Crohn’s

Wednesday, July 3, 2013

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, has enrolled and treated all patients in the phase I study BDP-PCD-01, a clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn’s disease. The SGX203 development program previously has received Fast Track and Orphan Drug designations from the FDA.

[Read More]

Soligenix initiates phase 1 study of SGX203 for pediatric Crohn’s disease

Thursday, May 16, 2013

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, has initiated the first clinical study for development of SGX203 (oral beclomethasone 17, 21-dipropionate or oral BDP) for the treatment of pediatric Crohn’s disease. The program has previously received Fast Track and Orphan Drug designations from the FDA for oral BDP as a treatment for pediatric Crohn’s disease.

[Read More]